Rifcin Capsule

About Rifcin 150 mg Capsule

Rifcin 150 mg capsules contain rifampicin, an antibiotic that works against certain bacteria, including the bacteria that cause tuberculosis. It is used as part of a treatment plan chosen by a doctor.

There are 18 brands of Rifampicin listed in Bangladesh. 3 of them have a lower unit price than Rifcin. The lowest listed price is Firifam 150 mg Tablet at ৳ 1 per unit.

What is Rifcin 150 mg Capsule?

Rifcin is a capsule made by Pharmadesh Laboratories Ltd. that contains rifampicin 150 mg. Rifampicin belongs to a group of anti-tubercular antibiotics. It works by blocking a step that susceptible bacteria need to build RNA, which stops them from making proteins and multiplying. Doctors prescribe it as part of a combination treatment plan rather than on its own. Because bacteria can become resistant, treatment is planned and monitored by a doctor. The capsule is available in a 4 x 10 pack. Ask your doctor or pharmacist about how this medicine fits into your treatment.

Uses of Rifcin

Rifcin is used in the treatment of tuberculosis, and in people who carry meningococcal bacteria without being ill. It is an antibiotic, not a general pain or fever medicine. It is given together with other medicines as part of a treatment plan. Do not start, stop or change it on your own. Your doctor will confirm what you need and how long you should take it.

How to use Rifcin

Take Rifcin exactly as your doctor tells you. The doctor decides the dose and the length of the course, and you should not change either yourself. Swallow the capsule with a full glass of water. Your doctor will tell you whether to take it with or without food and at what time. If you miss a dose, ask your doctor or pharmacist what to do. Do not take extra capsules to make up for a missed one.

Side effects of Rifcin

Rifcin can cause facial flushing and itching, with or without a rash, and flu-like symptoms such as fever, chills, headache, dizziness, bone pain, shortness of breath and feeling unwell. Stomach problems like nausea, vomiting, loss of appetite, diarrhoea and stomach discomfort can occur. Body fluids such as urine, faeces, sweat, saliva, sputum and tears may turn orange-red. Tell your doctor about any side effect that worries you.

Safety and precautions

Rifcin can affect the liver, so tell your doctor if you have liver disease or take other medicines, as some combinations raise the risk of liver problems. Your doctor may check your liver before and during treatment. Rifampicin can interact with many medicines, including some antivirals, so share your full medicine list. It is not for anyone with a history of allergy to rifampicin or related antibiotics. If you are pregnant, planning pregnancy or breastfeeding, speak to your doctor first, as rifampicin can affect the mother and baby near delivery.

Frequently asked questions

What does the generic name rifampicin mean?

Rifampicin is the generic name of the active ingredient in Rifcin. A generic name is the standard name of the medicine itself, while Rifcin is the brand name given by the company. Different brands may contain the same generic medicine.

What is Rifcin used for and what kind of medicine is it?

Rifcin is an anti-tubercular antibiotic. It is used in the treatment of tuberculosis and in people who carry meningococcal bacteria. It is given as part of a treatment plan with other medicines, and the doctor decides the course.

Who should avoid Rifcin or ask the doctor first?

People with a history of allergy to rifampicin or related antibiotics should not take it. Tell your doctor if you have liver disease, take other medicines, or are pregnant or breastfeeding. Ask your doctor before using it in any of these situations.

What is the price of Rifcin?

The listed price is ৳ 11.03. Ask your pharmacist about the current price and pack details. Do not compare prices in place of medical advice; your doctor decides whether this medicine is right for you.

Indications

In the treatment of both tuberculosis and the meningococcal carrier state, the small number of resistant cells present within large populations of susceptible cells can rapidly become the predominant type. Bacteriologic cultures should be obtained before the start of therapy to confirm the ... Read moreIn the treatment of both tuberculosis and the meningococcal carrier state, the small number of resistant cells present within large populations of susceptible cells can rapidly become the predominant type. Bacteriologic cultures should be obtained before the start of therapy to confirm the susceptibility of the organism to rifampinand they should be repeated throughout therapy to monitor the response to treatment. Since resistance can emerge rapidly, susceptibility tests should be performed in the event of persistent positive cultures during the course of treatment. If test results show resistance to rifampin and the patient is not responding to therapy, the drug regimen should be modified.

Pharmacology

Rifampicin suppresses initiation of chain formation for RNA synthesis in susceptible bacteria by binding to the β subunit of DNA-dependent RNA polymerase, thus blocking RNA transcription.

Dosage & Administration

Rifampin can be administered by the oral route or by IV infusion. IV doses are the same as those for oral.

Tuberculosis:
  • Adults: 10 mg/kg, in a single daily administration, not to exceed 600 mg/day, oral or IV
  • Pediatric Patients: 10–20 mg/kg, not to exceed 600 mg/day, oral or IV
It is recommended that oral rifampin be administered once daily, either 1 hour before or 2 hours after a meal with a full glass of water.

Rifampin is indicated in the treatment of all forms of tuberculosis. A three-drug regimen consisting of rifampin, isoniazid, and pyrazinamide is recommended in the initial phase of shortcourse therapy which is usually continued for 2 months. The Advisory Council for the Elimination of Tuberculosis, the American Thoracic Society, and the Centers for Disease Control and Prevention recommend that either streptomycin or ethambutol be added as a fourth drug in a regimen containing isoniazid (INH), rifampin and pyrazinamide for initial treatment of tuberculosis unless the likelihood of INH resistance is very low. The need for a fourth drug should be reassessed when the results of susceptibility testing are known. If community rates of INH resistance are currently less than 4%, an initial treatment regimen with less than four drugs may be considered.

Following the initial phase, treatment should be continued with rifampin and isoniazid for at least 4 months. Treatment should be continued for longer if the patient is still sputum or culture positive, if resistant organisms are present, or if the patient is HIV positive.

Interaction

May accelerate the metabolism and reduce the effect of drugs that are metabolised by CYP450 enzymes (e.g. quinidine, phenytoin, theophylline). Decreased concentrations of atovaquone and increased concentrations of rifampicin when taken concomitantly. Concurrent use of ketoconazole and rifampicin may result in decreased serum concentrations of both drugs. May decrease serum concentrations of enalaprilat. Reduced absorption by antacids. Increased risk of hepatotoxicity with halothane or isoniazid.

Contraindications

Rifampicin is contraindicated in patients with a history of hypersensitivity to rifampin or any of the components, or to any of the rifamycins. Rifampin is contraindicated in patients who are also receiving ritonavir-boosted saquinavir due to an increased risk of severe hepatocellular toxicity.

Rifampin is contraindicated in patients who are also receiving atazanavir, darunavir, fosamprenavir, saquinavir, or tipranavir due to the potential of rifampin to substantially decrease plasma concentrations of these antiviral drugs, which may result in loss of antiviral efficacy and/or development of viral resistance.

Side Effects

Facial flushing and itching, with or without a rash, flu-like syndrome characterised by episodes of fever, chills, headache, dizziness, bone pain, shortness of breath, and malaise; GI adverse effects (e.g. nausea, vomiting, anorexia, diarrhoea, epigastric distress), pseudomembranous colitis, eosinophilia, leucopenia, haemolytic anaemia; alterations in kidney function and renal failure, menstrual disturbances, oedema, myopathy, muscular weakness; orange-red discolouration of the urine, faeces, sweat, saliva, sputum, tears, and other body fluids; thrombophlebitis, local irritation and inflammation after prolonged IV infusion. Rarely, eye irritation and visual disturbances, anaphylaxis or shock.

Pregnancy & Lactation

Pregnancy: When administered during the last few weeks of pregnancy, rifampin can cause post natal hemorrhages in the mother and infant for which treatment with vitamin K may be indicated.

Nursing Mothers: Because of the potential for tumorigenicity shown for rifampin in animal studies, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.

Precautions & Warnings

Rifampicin has been shown to produce liver dysfunction. Fatalities associated with jaundice have occurred in patients with liver disease and in patients taking rifampin with other hepatotoxic agents. Patients with impaired liver function should be given rifampin only in cases of necessity and then with caution and under strict medical supervision. In these patients, careful monitoring of liver function, especially SGPT/ALT and SGOT/AST should be carried out prior to therapy and then every 2 to 4 weeks during therapy. If signs of hepatocellular damage occur, rifampin should be withdrawn.

In some cases, hyperbilirubinemia resulting from competition between rifampin and bilirubin for excretory pathways of the liver at the cell level can occur in the early days of treatment. An isolated report showing a moderate rise in bilirubin and/or transaminase level is not in itself an indication for interrupting treatment; rather, the decision should be made after repeating the tests, noting trends in the levels, and considering them in conjunction with the patient's clinical condition.

Rifampin has enzyme-inducing properties, including induction of delta amino levulinic acid synthetase. Isolated reports have associated porphyria exacerbation with rifampin administration.

Overdose Effects

Nausea, vomiting, abdominal pain, pruritus, headache, and increasing lethargy will probably occur within a short time after ingestion; unconsciousness may occur when there is severe hepatic disease. Transient increases in liver enzymes and/or bilirubin may occur. Brownish-red or orange discoloration of the skin, urine, sweat, saliva, tears, and feces will occur, and its intensity is proportional to the amount ingested.

Liver enlargement, possibly with tenderness, can develop within a few hours after severe overdosage; bilirubin levels may increase and jaundice may develop rapidly. Hepatic involvement may be more marked in patients with prior impairment of hepatic function. Other physical findings remain essentially normal. A direct effect upon the hematopoietic system, electrolyte levels, or acid-base balance is unlikely.

Facial or periorbital edema has also been reported in pediatric patients. Hypotension, sinus tachycardia, ventricular arrhythmias, seizures and cardiac arrest were reported in some fatal cases.

Storage Conditions

Store between 15-30° C. Avoid excessive heat and protect from light.

Alternative brands of Rifampicin

Other brands with the same generic name, cheapest first.

Firifam Tablet

150 mg

Rifampicin

Synovia Pharma PLC.

৳ 0.98 ৳ 1 2% off per unit

Firifam Tablet

450 mg

Rifampicin

Synovia Pharma PLC.

৳ 0.98 ৳ 1 2% off per unit

Rifatan Syrup

100 mg/5 ml

Rifampicin

G. A. Company Ltd.

৳ 28.8 ৳ 29.39 2% off per unit

Rifcin Syrup

100 mg/5 ml

Rifampicin

Pharmadesh Laboratories Ltd.

৳ 78.4 ৳ 80.00 2% off per unit

See all 18 brands

Medicine information is for reference only and is not medical advice. Always follow your doctor's prescription and check with a pharmacist.